# Cardiovascular and Renal Drugs Advisory Committee

October 16, 2007 National Labor College Silver Spring, Maryland

# **Draft Meeting Roster**

# CARDIOVASCULAR AND RENAL DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

# Steven D. Findlay, M.P.H.

Consumer Representative Health Policy Analyst Consumers Union Washington, DC

## John M. Flack, M.D., M.P.H.

Interim Chair, Department of Medicine University Health Center Wayne State University 4201 St. Antoine, Suite 2E Detroit, MI

# Robert A. Harrington, M.D., F.A.C.C. (Acting Chair)

Professor of Medicine, Division of Cardiology Department of Medicine Duke University Medical School Duke Clinical Research Institute Durham, NC

## Lynn Warner Stevenson, M.D.

Director, Cardiomyopathy Services Brigham and Women's Hospital Cardiovascular Division Boston, MA

# **TEMPORARY MEMBERS (Voting)**

## Henry R. Black, M.D.

Clinical Professor of Internal Medicine Division of Nephrology New York University School of Medicine New York, NY

## Abraham Michael Lincoff, M.D., F.A.C.C.

Professor of Medicine Department of Cardiovascular Medicine The Cleveland Clinic Foundation Cleveland, OH

## Emil P. Paganini, M.D., F.A.C.P., F.R.C.P.

Section Head, Dialysis and Extracorporeal Therapy Department of Nephrology and Hypertension The Cleveland Clinic Foundation Cleveland, OH

## John R. Teerlink, M.D.

Director, Heart Failure Clinic Director, Clinical Echocardiography Cardiology University of California, San Francisco San Francisco VA Medical Center San Francisco, CA

## Jeffrey Kopp, M.D.

Staff Clinician, Kidney Disease Section Kidney Disease Branch National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda, MD

# Cardiovascular and Renal Drugs Advisory Committee

# October 16, 2007 National Labor College Silver Spring, Maryland

# Draft Meeting Roster Page 2

# **TEMPORARY MEMBERS (Voting) Continued**

## Michael Proschan, Ph.D.

Biostatistician Biostatistics Research Branch National Institute of Allergy and Infectious Diseases Bethesda, MD

#### Malazia Scott

Patient Representative Tuscaloosa, AL

## Susan Shurin, M.D.

Deputy Director National Heart, Lung, and Blood Institute National Institutes of Health Bethesda, MD

# **INDUSTRY REPRESENTATIVE (Non-Voting)**

## John Neylan, M.D.

Industry Representative Vice President, Clinical Research and Development Wyeth Research Collegeville, PA

## **GUEST SPEAKER (Non-Voting)**

## Kerry Willis, Ph.D.

Senior Vice-President of Scientific Activities National Kidney Foundation New York, NY

## FDA PARTICIPANTS (Non-Voting)

## Norman Stockbridge, M.D.

Director, Division of Cardiovascular and Renal Drug Products FDA/CDER

## Nelson B. Watts, M.D., F.A.C.P.

Director University of Cincinnati Bone Health and Osteoporosis Center Cincinnati, OH

# Kathryn L. Weise, M.D., M.A.

Department of Pediatric Critical Care Medicine and Bioethics The Children's Hospital Cleveland Clinic Foundation Cleveland, OH

# Robert Temple, M.D.

Director, Office of Drug Evaluation I (ODEI) FDA/CDER